Your session is about to expire
← Back to Search
This trial is testing a new cancer treatment against the current best treatment for a particular type of aggressive breast cancer, to see if the new treatment is more effective and has fewer side effects.
- Breast Cancer
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a Location
Who is running the clinical trial?
- You have uncontrolled or serious heart problems.You are currently receiving treatment for cancer, in addition to this study.You had a major surgery or significant injury within the past 3 weeks before starting the study.Both males and females are eligible.You have a medical condition that would make it difficult for you to participate in the study or follow the study's rules.You have had another type of cancer, but it was treated and there is no sign of it now, or it has been more than 3 years since you had it.You are allergic to Dato DXd or any of its ingredients.You recently received a live vaccine within one month before starting the study treatment.You are taking long-term corticosteroids or other medications that suppress your immune system.You cannot receive treatment with PD-1/PD-L1 inhibitor therapy.You have a serious eye condition affecting the cornea.You have been tested for HER2 and the results show that you do not have high levels of the HER2 protein.You may be included in the study if you had a history of treated spinal cord compression or inactive brain metastases.You are expected to live for at least 12 more weeks.You have not received any chemotherapy or targeted therapy for breast cancer that has spread or cannot be surgically removed.Pembrolizumab is not approved for use in your country at the time of screening.You have a tumor that can be measured and has not been treated with radiation before. The tumor must be at least 10mm in size (except for lymph nodes which must be 15mm) and can be accurately measured with CT or MRI scans.Your overall physical health is good or slightly limited, and you have not experienced any decline in the past 2 weeks.Your breast cancer doesn't have a specific protein called PD-L1, or you have previously received treatment with a PD-1/PD-L1 inhibitor and your cancer has come back.
- Group 1: Dato-DXd
- Group 2: Investigator's Choice of Chemotherapy (ICC)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you please elaborate on any potential risks associated with Dato-DXd?
"Dato-DXd is classified as a Phase 3 trial medication, so it has received a 3 for safety. This decision was made because there is both efficacy and safety data available."
How many different facilities are responsible for administering this clinical trial?
"There are a total of 48 clinical trial sites for this medication, which are situated in locations such as Greenfield Park, Montreal, and Miami. If you are selected for the trial, it would be ideal to choose a location close to you to reduce travel demands."
How many people fit the criteria to be a part of this test group?
"The information available on clinicaltrials.gov indicates that this trial is still enrolling patients. This study was first announced on May 16th, 2022 and was last updated on October 26th, 2022. The researchers are looking for 600 individuals to participate across 48 different sites."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends